HIV Accelerated Liver Disease in Uganda
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01524562|
Recruitment Status : Completed
First Posted : February 2, 2012
Last Update Posted : April 5, 2018
- Liver disease is a leading cause of death in people who have the human immunodeficiency virus (HIV). It especially affects those who have both HIV and hepatitis B or C viruses. Most research on HIV-related liver disease has been conducted in North America and Europe. However, HIV-related liver disease in Uganda and other African nations may involve other diseases that are not common in the West, and may not involve hepatitis B or C. Researchers want to study HIV-related liver disease in Uganda to learn more about the differences between Western and African trends of this disease.
- To study HIV-related liver disease in rural Uganda.
- Individuals at least 18 years of age who were tested for possible liver disease. Some participants will have HIV infection; others will be uninfected.
- All participants will be from rural areas of Uganda.
- Participants will have at least two study visits.
- Participants will have a physical exam and medical history. They will complete a questionnaire about health and quality of life. Blood, urine, and stool samples will be collected. Participants will also have a liver scan to check for liver scarring, and an ultrasound to take images of the liver.
- Participants who may have liver disease will visit a local hospital for more tests. A liver biopsy will be performed to collect liver tissue samples.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||786 participants|
|Official Title:||HIV-Accelerated Liver Disease in Uganda|
|Study Start Date :||December 20, 2011|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01524562
|United States, Maryland|
|National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Steven J Reynolds, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|